Efficacy of long-term treatment with istradefylline and analysis of the expression of A2A receptor protein and post-transcriptional DNA methylation
Objective: To evaluate the pharmacological properties of Adenosine A2A receptor antagonist, istradefylline (IST), and analyze A2AR protein levels of peripheral lymphocytes and the frequency of…Adenosine A2A receptor antagonist istradefylline might have efficacy to fatigue and depression in some patients of Parkinson’s disease
Objective: To evaluate the efficacy of istradefylline, a selective adenosine A2A receptor antagonist, for fatigue and depression in Parkinson's disease (PD) patients. Background: Istradefylline is…Detailed evaluation of dyskinesias using multiple endpoints in a randomized, placebo-controlled trial of Parkinson’s disease patients with motor fluctuations
Objective: To analyze all dyskinesia data from a Phase 2b trial of fluctuating Parkinson patients in order to understand the overall impact a study drug…Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations
Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson’s disease patients with motor fluctuations (TOZ-PD)
Objective: To identify and implement strategies to improve the efficiency of drug development in Phase 3 studies. Background: Conducting global clinical trials can be challenging,…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.